ArticleInternational journal of epidemiology2025
Evaluating potential associations between prior maternal yellow fever vaccination and protection against infant adverse outcomes following Zika virus antenatal exposure.
Article in International journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to Comment on 'Evaluating potential associations between prior maternal yellow fever vaccination and protection against infant adverse outcomes following Zika virus antenatal exposure'.International journal of epidemiology · 2026Article
- Zika virus infection in early pregnancy increases the likelihood of persistent neutralizing antibodies.PLoS neglected tropical diseases · 2026Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
27 authors.
Funding
Abstract
backgroundDuring the Zika virus (ZIKV) epidemic in Brazil, regional disparities in yellow fever (YF) vaccination coverage and microcephaly incidence led to the hypothesis that maternal YF vaccination could protect against ZIKV infection and microcephaly.
methodsThis case-cohort study was conducted in Campo Grande, Brazil, from 2018 to 2022 and included children with confirmed in utero ZIKV exposure (2015-2018) and a matched control group, totaling 129 mother-child dyads. Maternal blood samples were collected to assess ZIKV exposure and neutralizing YF vaccine-induced antibody (NAb) titers. Associations between YF NAb titer, congenital anomalies, and infant neurodevelopmental delay were evaluated.
resultsMean YF NAb titers differed between ZIKV-exposed and unexposed mothers (P = .011) and between mothers of children with and without microcephaly (P = .037). Congenital anomalies were associated with lower YF NAb titers (P < .001), prenatal ZIKV exposure (P = .001), and lower family income (P < .001). Neurodevelopmental delay was associated with prenatal ZIKV exposure [adjusted odds ratio (aOR): 4.35, 95% confidence interval (CI): 1.65-13.03], prenatal care with at least six visits (aOR: 0.22, CI: 0.06-0.78), and adequate or large for gestational age birth weight (aOR: 0.09, CI: 0.01-0.44).
conclusionDifferences in maternal YF NAb titers by ZIKV exposure and microcephaly suggest a potential protective effect of YF vaccination against ZIKV acquisition and/or development of microcephaly, which should be investigated. Developmental delay, although not associated with maternal YF immunity, was associated with antenatal ZIKV exposure, less prenatal care visits, and being small for gestational age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.